Abstract We examined changes in nuclear peroxisome proliferator-activated receptor c (PPARc) in the striatum in methamphetamine (METH)-induced dopaminergic neurotoxicity, and also examined effects of treatment with drugs possessing PPARc agonistic properties. The marked reduction of nuclear PPARc-expressed cells was seen in the striatum 3 days after METH injections (4 mg/kg 9 4, i.p. with 2-h interval). The reduction of dopamine transporter (DAT)-positive signals and PPARc expression, and accumulation of activated microglial cells were significantly and dose-dependently attenuated by four injections of a nonsteroidal anti-inflammatory drug and a PPARc ligand, ibuprofen (10 or 20 mg/kg 9 4, s.c.) given 30 min prior to each METH injection, but not by either a low or high dose of aspirin. Either treatment of ibuprofen or aspirin, that showed no effects on METH-induced hyperthermia, significantly blocked the METH-induced striatal cyclooxygenase (COX) expression. Furthermore, the treatment of an intrinsic PPARc ligand 15d-PG J2 also attenuated METH injections-induced reduction of striatal DAT.
Introduction
Methamphetamine (METH) is a drug of abuse that causes damage to striatal dopaminergic neuronal systems. Regarding the mechanism responsible for METH-induced neurotoxicity in dopamine terminals, various hypotheses have been proposed, including hyperthermia, glutamate release, reactive oxygen species (ROS), reactive nitrogen species, apoptosis-related molecules and dopamine quinone [1] [2] [3] [4] . Furthermore, a number of studies showed the involvement of inflammatory molecular and/or cellular events in METH-induced dopaminergic neurotoxicity. We have previously shown that METH induced activation of ROS-and inflammation-inducible transcription factors, nuclear factor jB (NF-jB) and its related apoptosis-promoting factor, p53, and that the induction of these factors was significantly attenuated in Cu,Zn-superoxide dismutase transgenic mice [5, 6] . Of related interest, NF-jB activated by the inflammatory stimuli and ROS in microglial cells, oligodendrocytes and neurons promotes the transcription of inflammatory cytokines (interneukin (IL)-1b, IL-6, interferon-c, tumor necrosis factor-a (TNF-a)), apoptosispromoting factors (p53, Bax), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) to generate prostaglandins (PGs), nitric oxide (NO • ) and consequently induce inflammatory cytokines [7] . The NO
• generation via iNOS activation was reported to be involved in METH-induced neurotoxicity [8, 9] , and METH caused overexpression of COX-2 [10] . METH injections result in activation of microglia in the striatum [11] [12] [13] , while METH-induced dopaminergic neurotoxicity was attenuated by the treatment with minocycline [14] and in IL-6 knockout mice [15] . Nonsteroidal anti-inflammatory drugs (NSAIDs) as COX inhibitors exert inhibitory effects against inflammatory mediators-induced increases in iNOS activity and NO
• production [16, 17] . Therefore, we previously examined possible protective effects of NSAIDs against METH-induced dopaminergic neurotoxicity, and revealed that marked reduction of dopamine transporter (DAT) and accumulation of microglial cells in the striatum after METH injections were significantly and dose-dependently attenuated by pretreatment of NSAID ketoprofen or indomethacin prior to each METH injection [11, 18] . However, another NSAID as a representative COX inhibitor, aspirin showed no attenuating effects on METH-induced reduction of DAT and microglial activation. These results imply that the protective effects of former two NSAIDs against METHinduced neurotoxicity are not based on their COX-inhibiting property. Among NSAIDs, indomethacin, ibuprofen and naproxen exert neuroprotective effects in in vitro and in vivo experiments as ligands for peroxisome proliferatoractivated receptor c (PPARc) [19] [20] [21] [22] . PPARc is an inhibitory transcription factor that antagonizes the activity of NF-jB, AP-1, STAT-1 and NF-AT [23, 24] and that inhibits gene expression of inflammatory cytokines such as IL-1b, IL-6 and TNF-a [25] . Therefore, we examined changes in nuclear PPARc expression in the striatum after repeated METH injections and possible neuroprotective properties of other NSAID as a PPARc ligand, ibuprofen and an intrinsic PPARc ligand, 15-deoxy-D 12-14-PG J2 (15d-PG J2) against METH-induced neurotoxicity in the present study.
Experimental Procedures

Drug Administration and Measurement of Rectal Temperature
Male BALB/c mice (8 weeks old; Charles River Japan Inc., Yokohama, Japan) were used in the present study. All animal use procedures were in strict accordance with The Guidelines for Animal Experiments at Okayama University Medical School. Mice were given repeated METH injections (4 mg/kg 9 4, i.p. with 2-h interval) or the same volume of saline. The animals were also subcutaneously administered with NSAIDs: aspirin (40 or 100 mg/kg 9 4) or ibuprofen (10 or 20 mg/kg 9 4) suspended in 0.5% methylcellulose 30 min prior to each METH injection, respectively. These doses of NSAIDs were chosen according to their doses for clinical use. For the experiment using intrinsic PPARc ligand, 15d-PG J2 (1 mg/kg 9 4) dissolved in dimethylsulfoxide (DMSO) and diluted with saline (10% DMSO-containing saline) was intraperitoneally administered 30 min prior to each METH injection. Rectal temperature was recorded 30 min before or after each METH injection using a monitoring thermometer (Bio Research Center, Osaka). The animals were returned to the same home cage after the final measurement of rectal temperature.
Immunohistochemistry
Three days after the last METH injection, mice were transcardially perfused with saline followed by a fixative containing 4% paraformaldehyde, 0.35% glutaraldehyde in 0.1 M phosphate buffer (PB: pH 7.4) under deep pentobarbital anesthesia. After the perfusion, the brains were quickly removed from the skull, post-fixed for 24 h in a fixative containing 4% paraformaldehyde in 0.1 M PB (pH 7.4), and then cryoprotected in 15% sucrose in PB for about 48 h. Brains frozen with powdered dry ice were cut coronally on a cryostat at levels containing the mid-striatum (?0.6 to ?1.0 mm from the bregma) at 20-lm thickness.
DAT, COX-1, COX-2 or PPARc-immunopositive cells and microglial cells in the striatum were stained by standard immunohistochemistry [11, 26] . The sections were soaked in 10 mM phosphate buffered saline containing 0.2% Triton X-100 (PBST) for 1 h, and then incubated in 0.5% H 2 O 2 in PBST for 30 min at room temperature. After washing with PBST (3 9 10 min), the sections were incubated in 1% normal rabbit serum in PBST for 30 min for DAT-, COX-1-, COX-2-and microglia-staining protocols. For PPARc-staining, the sections were incubated in 1% normal goat serum in PBST for 30 min. Sections were then exposed to goat anti-DAT polyclonal antibody (diluted 1:200 in PBST; Santa Cruz Biotechnology, Santa Cruz, CA) or to rat anti-CD11b (Mac1) polyclonal antibody (diluted 1:10,000 in PBST; Serotec, Oxford, UK) for microglia for 2 h at room temperature. For COX-1, -2, or PPARc-staining, sections were incubated with goat anti-COX-1 or anti-COX-2 polyclonal antibody (diluted 1:500 in PBST; Santa Cruz Biotechnology) or rabbit anti-PPARc polyclonal antibody (diluted 1:500 in PBST; Cell Signaling, Boston, MA) for 16 h at 4°C. After incubation with the primary antibody, sections were washed for 5 9 5 min in PBST before being incubated with rabbit anti-goat IgG biotinylated secondary antibody for DAT, COX-1 and COX-2, goat anti-rabbit IgG biotinylated secondary antibody for PPARc or rabbit anti-rat IgG biotinylated secondary antibody for microglia (diluted 1:1,000 in PBST:Vector Laboratories) for 1.5 h at room temperature, respectively. Following washes in PBST (3 9 10 min), the The relative density of DAT-positive signals in the quadrant (mediodorsal, laterodorsal, medioventral or lateroventral) of the mid-striatum was semi-quantified using a microscope at a magnification of 940 and a Macintosh computer-based image analysis system (Image 1.56). Each side of the mid-striatum on the digitized image was separately outlined with a screen cursor driven by a hand-held mouse and relative density in the mid-striatum was measured by subtracting the background density in the lateral ventricle of each slice [26] . COX-1, COX-2 or PPARcimmunopositive cells or CD11b (Mac1)-immunoreactive microglial cells with both the nucleus and dendrites in each quadrant of the mid-striatum were counted manually using a microscope at a magnification of 9200 with a superimposed grid [26] . Counting was performed blindly. Statistical analyses for indices were performed using oneway ANOVA followed by Fisher's PLSD post hoc test.
Western Blot Analysis
One day after the last METH injection, nuclear protein was extracted from striatal tissue of the drug-treated mice [5, 6] . Western blot analysis was performed as described previously [4] . In brief, nuclear extract (2.5 lg) was loaded on 10% sodium dodecyl sulfate-containing polyacrylamide gels and blotted onto polyvinylidene difluoride membranes (Hybond-P, Amersham, Buckinghamshire, UK). Blots were incubated with rabbit anti-PPARc polyclonal antibody (1:200 dilution, Santa Cruz Biotechnology) or goat anti-Lamin B1 polyclonal antibody (1:200 dilution, Santa Cruz Biotechnology), and then reacted with the corresponding secondary antibody conjugated to horseradish peroxidase. After washing with 20 mM Tris-buffered saline containing 0.1% Tween 20, blots were developed using the ECL Western blotting detection system (Amersham). For quantitative analysis, the ratio for PPARc protein (relative density of the signal) and the constitutively expressed Lamin B1 protein were calculated to normalize for loading and transfer artifacts introduced in western blotting.
Results
METH-Induced Changes in Striatal PPARcImmunopositive Cells and Effects of NSAIDs
Our previous study showed that a PPARc ligand, indomethacin had neuroprotective effects against METH-induced dopaminergic neurotoxicity [18] . Therefore, we examined changes in nuclear PPARc expression in the striatum after repeated METH injections and also examined effects of ibuprofen or aspirin other NSAID with or without PPARc agonistic property on the PPARc expression, respectively. Marked reduction of PPARc-immunopositive cells were observed in whole areas of the mid-striatum 3 days after the repeated METH injections (4 mg/kg 9 4, i.p. with 2-h interval) (Fig. 1, top panel) . Although the treatment with aspirin or ibuprofen alone showed no effects on the striatal PPARc expression, the METH-induced reduction of the number of PPARc-positive cells was almost completely prevented by the treatment with ibuprofen (20 mg/kg 9 4) given 30 min prior to each METH administration (Fig. 1 , middle panel). Western blot analysis using the nuclear protein also showed marked decrease in nuclear PPARc protein in the striatum 1 day after the METH injections and the preventing effects of the ibuprofen treatment on the reduction of the protein ( Fig. 1, bottom panel) . On the other hand, four injections of aspirin (100 mg/kg 9 4, s.c.) showed no effects on the METH injections-induced decrease in the striatal PPARc-immunopositive cells.
Effects of NSAIDs on METH-Induced Hyperthermia
Repeated injections of METH (4 mg/kg 9 4, i.p. at 2-h intervals) produced a significant hyperthermia in mice at 30 min after the second and the third METH injections (group 9 time, F (35, 289) = 4.077, P \ 0.0001, two-way ANOVA) (Fig. 2 ). The treatment with aspirin (100 mg/kg 9 4, s.c.) or ibuprofen (20 mg/kg 9 4, s.c.) alone showed no effects on rectal temperature. The METH-induced hyperthermic responses at 30 min after the second and the third METH injections were not ameliorated by injections of either aspirin (100 mg/kg 9 4, s.c.) or ibuprofen (20 mg/kg 9 4, s.c.) given 30 min prior to each METH injection (vs. vehicle ? METH-treated group, P = 0.1178 or P = 0.8325, respectively, two-way ANOVA).
Effects of NSAIDs on METH-Induced Reduction in Striatal DAT
Repeated METH injections (4 mg/kg 9 4, i.p. with 2-h interval) caused rapid reduction of DAT-positive signals in the striatum, starting at 1 day (data not shown), and reaching the lowest levels at 3 days after the cessation of injections (Fig. 3) . Marked reduction of DAT signals was observed in all four striatal quadrants (laterodorsal = mediodorsal [ lateroventral [ medioventral) of mid-striatum 3 days after the METH injections (Fig. 3) . The reduction of DAT signals in all quadrants of the striatum after repeated METH injections was significantly and dose-dependently attenuated by four injections of ibuprofen (10 or 20 mg/kg 9 4, s.c.) given 30 min prior to each METH injection (Fig. 3) . On the other hand, four injections of aspirin (40 or 100 mg/kg 9 4, s.c.) showed no effects on the repeated METH injections-induced reduction of striatal DAT (Fig. 3) . Furthermore, either treatment with aspirin or ibuprofen alone showed no effects on the DAT-positive signals in the striatum.
Effects of NSAIDs on METH-Induced Accumulation of Microglial Cells in the Striatum
Accumulation of CD11b (Mac1)-immunoreactive activated microglial cells was observed in all quadrants of midstriatum 3 days after the repeated METH injections (4 mg/ kg 9 4, i.p. with 2-h interval) (Fig. 4) . In either striatal area, the METH-induced increase in the number of CD11b-positive microglial cells was significantly and dose-dependently attenuated by injections of ibuprofen (10 or 20 mg/kg 9 4) given 30 min prior to each METH administration, but not by either dose of aspirin (Fig. 4) . Either treatment with aspirin or ibuprofen alone showed no effects on the Mac1-positive microglial cells in the striatum.
Effects of NSAIDs on METH-Induced Increase in Striatal COX Expression
Marked increases in COX-1-expressed cells were observed in all quadrants of the striatum 3 days after the repeated METH injections (4 mg/kg 9 4, i.p. with 2-h interval) (Fig. 5) . The repeated METH injections-induced increase in the number of COX-1-expressed cells was significantly inhibited by four injections of aspirin (100 mg/kg 9 4) in the lateroventral quadrant of the striatum and by injections of ibuprofen (20 mg/kg 9 4) in the laterodorsal and medioventral quadrants of the striatum (Fig. 5) . Regarding COX-2 expression, the treatment with aspirin (100 mg/ kg 9 4) or ibuprofen (20 mg/kg 9 4) alone reduced the number of COX-2-positive cells in the medial parts of the striatum (Fig. 6 ). The repeated METH injections (4 mg/ kg 9 4, i.p. with 2-h interval) increased in the number of COX-2-expressed cells significantly in the lateral striatum, similar to the increases in COX-1 expression (Fig. 6 ). Either treatment of aspirin (100 mg/kg 9 4) or ibuprofen (20 mg/kg 9 4) almost completely blocked the METHinduced increases in the COX-2-expressed cells in the lateral striatum.
Effects of Intrinsic PPARc Ligand, 15d-PG J2 on METH-Induced Reduction in Striatal DAT
The marked reduction of DAT signals in the striatum after repeated METH injections (4 mg/kg 9 4, i.p. with 2-h interval) was significantly attenuated by four injections of intrinsic PPARc ligand, 15d-PG J2 (1 mg/kg 9 4, i.p.) given 30 min prior to each METH injection, although the treatment with the drug alone showed no effects on the striatal DAT expression (Fig. 7) .
Discussion
The main findings of this article are that (1) repeated METH injections caused drastic reduction of nuclear PPARc expression in the striatum; (2) four injections of ibuprofen prior to each METH injection dose-dependently attenuate the reduction of striatal DAT levels, decrease in nuclear PPARc-expressed cells and accumulation of activated microglial cells in the striatum caused by the repeated METH injections; and (3) the treatment with an intrinsic PPARc ligand 15d-PG J2 also attenuated METH injections-induced reduction of striatal DAT. The preventing effects of ibuprofen against METHinduced reduction of striatal dopamine terminals and striatal microglial activation in the present study are similar to the attenuating effects of indometacin injections against the same indices [18] . It has been reported that the similar repeated injection of METH caused the induction of COX-2 protein in the striatum [10] . However, other NSAID, aspirin which is a representative COX inhibitor show no attenuating effects on METH-induced reduction of DAT and accumulation of activated microglial cells in the striatum at either dose (Figs. 3, 4) , coinciding with our previous report [18] . Either treatment of ibuprofen or aspirin significantly blocked the METH injections-induced increases in both COX-1-positive and COX-2-expressed cells in the striatum (Figs. 5, 6 ). Furthermore, the hyperthermic responses after the second and the third METH injections were not ameliorated by treatment with either ibuprofen or aspirin (Fig. 2) . Therefore, these resulting data suggest that the protective effects of ibuprofen against METH-induced neurotoxicity in striatal dopamine terminals and microglial activation are not based on its COXinhibiting property or its hypothermic effect.
NSAIDs exert heterogeneous neuroprotective actions against dopaminergic neurotoxicity by their various pharmacological properties; not only their COX-inhibiting effect but also their inhibitory effects against NO
• -associated changes through multiple action sites such as NF-jB or NOS, agonistic effects on PPARc and possible suppressive effects against DA quinone generation in addition to some as yet unknown properties [27] [28] [29] . In other words, among all types of NSAIDs that possess COX-inhibiting action, none of them can ever show the same protective effects; the neuroprotective action of each NSAID may depend on its specific pharmacological profile besides its COX-inhibiting effect. On the potential therapeutic efficacy of COX-2 inhibitors in parkinsonian models, Esposito et al. [28] have clearly reviewed the controversial experimental results. A number of experimental data suggested the therapeutic efficacy of preferential or selective COX-2 inhibitors against neurodegeneration related to inflammatory reaction in parkinsonian models, while some nonselective NSAIDs and preferential or selective COX-2 inhibitors showed no protective effects against dopaminergic neurotoxin-induced neurotoxicity. Furthermore, pre-administration of selective COX-2 inhibitor (celecoxib) did not halt repeated METH injections-induced neurodegeneration, rather exacerbated METH-induced dopamine depletion [30] . This report strongly suggests a COX-independent mechanism on the protective effects of ibuprofen against METH-induced striatal DAT reduction and microglial activation.
The present study revealed that repeated METH injections (4 mg/kg 9 4, i.p. with 2-h interval) caused marked decrease in nuclear PPARc expression in the striatum at 1 day and 3 days after the METH injections (Fig. 1) . Since the nuclear PPARc expression was decreased at earlier time point at 3 h after single METH injection (data not shown), METH injection may inhibit PPARc activation or nuclear translocation but not affect its protein synthesis. Furthermore, the METH-induced reduction of striatal PPARc expression was almost completely prevented by the treatment with ibuprofen (Fig. 1) . Among NSAIDs, ibuprofen and indomethacin are known to exert neuroprotective effects acting as ligands for PPARc [20] [21] [22] , which is a ligand-activated inhibitory transcription factor to inhibit the activity of NF-jB, AP-1, STAT-1 and NF-AT [23, 24] . Taken together with the attenuating effects of treatment with ibuprofen and indomethacin against METH-induced neurotoxicity and microgliosis in the present study and our previous report [18] , it is suggested that the neuroprotective effects of both drugs against METH neurotoxicity and microgliosis are based, in part, on their anti-inflammatory PPARc agonistic properties. This idea is supported by the present experimental results that the treatment of intrinsic PPARc ligand 15d-PG J2 also significantly prevented METH injections-induced reduction of striatal DAT (Fig. 7) .
In a previous report, we showed that METH injections (94 with 2-h interval) caused dose-dependent activation of striatal NF-jB which is a key transcription factor in the inflammatory process activated by ROS [5] . As described above, NF-jB promotes induction of iNOS to generate NO
• to induce various inflammatory cytokines, and consequently leads to a cytotoxic cycle [7] . It is well known that activated microglial cells produce various inflammatory cytokines, i.e. IL-1b, IL-6, and NO
• radicals, vice versa. Indeed, METH induced expression of IL-1b mRNA in the rat brain [31] . Cadet and his colleagues reported that METH-induced neurotoxicity and gliosis were attenuated in IL-6 knockout mice [15] and that METH injection increased the expression of transcription factor NF-AT, which promotes IL-4 expression [32] , suggesting involvement of inflammatory cytokines in METHinduced neurotoxic cascade. The activity of transcription factors, AP-1, NF-jB and NF-AT, which are activated by METH injections [5, 32, 33] , is known to be antagonized by the inhibitory transcription factor PPARc [23, 24] . Therefore, the present results suggest the possibility that the protective effects of ibuprofen against METH-induced neurotoxicity and microgliosis might be based on the direct or indirect inhibition against inflammatory cytokines and microglia activation via its property as PPARc agonist, but not due to the COX-inhibiting property.
Moreover, it has been revealed that ibuprofen causes cell cycle arrest of microglial cells to inhibit microglial proliferation [34] . Therefore, it is possible that the attenuating effects of ibuprofen treatment against METH-induced neurotoxicity and microgliosis are based on not only its anti-inflammatory PPARc agonistic property but, in part, its inhibitory action on microglial proliferation.
In conclusion, this study suggest that the treatment with ibuprofen, a commonly used nonprescription NSAID, can attenuate METH-induced neurotoxicity and microgliosis in the striatum probably, in part, via its property as a PPARc agonist, but not due to its COX-inhibiting property. Further study using PPARc antagonists would clarify the involvement of PPARc in the protective effects of ibuprofen. Furthermore, this is the first demonstration that repeated METH injections caused marked decrease in nuclear PPARc expression in the striatum, and the treatment with an intrinsic PPARc ligand 15d-PG J2 attenuated METHinduced dopaminergic neurotoxicity. When taken together with previous observations showing attenuating effects of indomethacin acting as a PPARc agonist against METHinduced neurotoxicity and microgliosis [18] , this study provides a new strategy against METH-induced neurotoxicity by using PPARc agonists including ibuprofen. 
